Connection between immune system and Immune based therapy or biological therapy

The ultimate cancer immunotherapy agent should be capable to differentiate between cancer and normal cells like specificity, be effective sufficient to kill small or large numbers of tumor cells like sensitivity, and lastly be competent to prevent recurrence of the tumor like durability. Currently, tumor immunology and immune based therapy is one of the most exciting and rapidly growing fields. 

The immune system is generally divided into two primary components such as the innate immune response or system, and the extremely precise but more gradually developing adaptive or acquired immune response or system. Innate immunity is rapidly acting but typically not very specific and includes physicochemical barriers (eg, skin and mucosa), blood proteins such as complement, phagocytic cells (such as neutrophils, macrophages, dendritic cells, and natural killer cells), and cytokines, which synchronize and regulate the cells involved in innate immunity. Adaptive immunity is thought of as the acquired arm of immunity, which allows for exquisite specificity, an ability to remember the previous existence of the pathogen and differentiate self from non-self and, significantly, the ability to respond more vigorously on repeat exposure to the pathogen.

The thought that the immune system may actively prevent the development of neoplasia is termed as cancer immunosurveillance. There are several nonspecific tumor immune based therapy approaches ranging from biological response modifiers (BRM) to recombinant cytokines.

 

www.gapsos.com

Biological response modifiers are molecules that can modify the biological response of cells to changes in its external environment, which in the perspective of cancer immune based therapy, might easily extent specific and non specific immune based therapies.

A number of investigations using recombinant cytokines, growth factors, or hormones in various fashions for human and veterinary cancer patients have been reported up to now. Many have investigated the in vitro and/or in vivo effects of the soluble cytokine (for example interferons, IL 2, IL 12, IL 15 and liposome encapsulation of the cytokine (for example liposomal IL 2) or use a virus, cell, plasmid, liposome DNA complex, or other mechanism to express the cytokine (such as recombinant poxvirus expressing IL 2).

Similar to any type of anticancer treatment, immunotherapy appears to work best in a minimal residual disease setting, signifying its most appropriate use will be in an adjuvant setting with local tumor therapies such as surgery or radiation therapy.

Global Allied Pharmaceuticals (GAP) consist an expert team of oncologists and researchers. To know more information about immunotherapy related services, you can contact on www.gapsos.com.